Relay Therapeutics, Inc. reported $10M of revenue over the trailing twelve months, +24% on the year before. 8 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $10M (to Q2 2026). Net income: −$286M, trailing twelve months to Q2 2026. Free cash flow: −$236M, trailing twelve months to Q4 2025. EPS: −$1.56, trailing twelve months to Q2 2026.

RLAYRelay Therapeutics, Inc.

Healthcare

$18.17+179% 1Y

$18.17

$6.0552 weeks$20.77

RLAY as reported

Relay Therapeutics, Inc. reported $10M of revenue over the trailing twelve months, +24% on the year before. 8 reported series are charted on this page, each one as filed.

$10M

Revenue, trailing twelve months · to Q2 2026 · +24% against the twelve months before

Net income: −$286M
Net income · −8.2% year on year · trailing twelve months to Q2 2026
Free cash flow: −$236M
Free cash flow · trailing twelve months to Q4 2025
EPS: −$1.56
EPS · −19% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for RLAY, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$10M	+24%	Q2 2026
Net income	−$286M	−8.2%	Q2 2026
EPS	−$1.56	−19%	Q2 2026
Operating margin	2282322%	n/a	Q1 2024 · 9 quarters behind
Net margin	2066412%	n/a	Q1 2024 · 9 quarters behind
ROE	−43%	n/a	Q2 2026
ROA	−39%	n/a	Q2 2026
Free cash flow	−$236M	n/a	Q4 2025

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.